Citius Pharmaceuticals, Inc.-Miami Lunch

444 Brickell Avenue,Miami FL 33131

09 February, 2022

Description

Come learn more about Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) and their management team *Due to limited seating, please make sure each individual registers accordingly. You will not be permitted to attend the event without proper registration. Citius Pharmaceuticals, Inc.  (NASDAQ:  CTXR)Wednesday, February 9, 2022The Capital Grille444 Brickell AveMiami, FL 33131Promptly at 12:00 PMJoin Citius Pharmaceuticals, Inc. Chairman Leonard Mazur for this exclusive corporate presentation, followed by a Q & A session moderated by Bear Creek Capital, featuring questions taken from the audience. We hope you can join our presentation About Citius Phamaceuticals, Inc.Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed subject treatment in its Pivotal Phase 3 trial. Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute respiratory distress syndrome (ARDS). Company HighlightsCitius is committed to developing therapies for unmet medical needs with cost-effective products in high growth categories with low developmental risk. Mino-Lok product has advanced to Phase 3 clinical studies. CITI-101 (Mino-Wrap) is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. More information on this product will be coming soon. CITI-002 is being developed for symptomatic relief of hemorrhoids. CITI-002 combines the high-potency steroid, halobetasol, with lidocaine. Citius has an experienced management team with demonstrated success in developing and commercializing novel pharmaceutical products. In the NewsCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2021 Financial Results and Provides Business Update Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls Temple University Renames College of Liberal Arts Main Campus Building in Honor of Citius Pharmaceuticals Executive Chairman Leonard Mazur Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications Citius Pharmaceuticals, Inc. Reports Third Fiscal Quarter 2021 Financial Results and Provides General Business Update Citius Pharmaceuticals, Inc. Provides First Half 2021 Business Update, Highlights Upcoming Milestones Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned Citius Pharmaceuticals Expands Scientific Advisory Board with Addition of Dr. John Laffey, Expert in Stem Cell and Gene Therapies for ARDS Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial Citius Pharmaceuticals to be Added to Russell 2000® Index Citius Pharmaceuticals to Feature Updated Positive Interim Results of i-MSC Study During Poster Presentation at International Society for Cell and Gene Therapy Presentation Format:  12:00 p.m. to 1:30 p.m. – Lunch & Presentation Contact: Raymond Oliver CEO, Bear Creek Capital 321-439-2120 [email protected]